MOR: רווח נקי למניה (EPS TTM) MorphoSys AG

MorphoSys AG is optimizing its production links by eliminating dependence on external vendors. GURU.Markets quotes drive this chart, where the 12-month rolling net income per share demonstrates the growth trajectory, and -3.50 represents the current level of the metric. The business relies on the HuCAL and Ylanthia ecosystem with strong partner lock-in, while ensuring strict temperature control during drug delivery.

The investment attractiveness of MorphoSys AG (MOR) is based on the efficiency of targeted antibody development and the stability of partner royalties. Net income per share (TTM) measures the portion of annual income attributable to a single security. By analyzing this 12-month net income per share chart, an investor can see the actual yield adjusted for the number of shares. A diversified pipeline minimizes the volatility of this metric, confirming the stability of the company's capital.